Group 1: Impact of Tariff Policies - Changes in tariff policies present both opportunities and challenges for the scientific instrument industry, leading to increased procurement costs for imported instruments and related consumables [2] - The high dependence on imports in the scientific instrument sector creates uncertainty and insecurity among domestic users, which can be strategically advantageous for local manufacturers [2] - The company plans to increase R&D investment in 2025 to capitalize on these strategic opportunities and enhance product offerings tailored to domestic customer needs [2] Group 2: Business Structure Adjustments - Recent adjustments in the company's business structure have resulted in improved gross margins and a recovery in net profit margins [3] - The company aims to further invest in its advantageous business segments to promote growth while maintaining a stable recovery in net profit margins [3] Group 3: Carbon Monitoring Equipment - The subsidiary Lingxi Optoelectronics has developed high-precision greenhouse gas analysis instruments, with significant contract growth expected in 2024 due to favorable domestic carbon monitoring policies [3] - The company anticipates a positive outlook for its carbon monitoring segment as market policies are implemented [3] Group 4: Market Demand and Product Development - The laboratory instrument sector is projected to maintain good growth, particularly in mass spectrometry, which has strong technical advantages and customer recognition [3] - The environmental monitoring segment achieved approximately 10% growth last year, with stable market conditions and a focus on increasing market share [3] Group 5: Future of Intelligent Instruments - The company envisions a future where analytical instruments evolve into "analysis robots," integrating AI capabilities for enhanced decision-making and operational efficiency [4] - Current developments include a modern environmental management model that leverages AI and new intelligent monitoring equipment such as drones and robotic dogs [4] Group 6: Goodwill Impairment - The company's current goodwill is approximately 200 million, primarily related to specific subsidiaries, with future impairment assessments dependent on individual company performance [4]

Investment Rating - The investment rating for the company is not explicitly stated in the report [1] Core Views - The company achieved significant growth in 2024, with total revenue reaching 3.614 billion yuan, a year-on-year increase of 13.58%, and a net profit attributable to shareholders of 207 million yuan, up 164.11% year-on-year [1][3] - The company is focusing on high-end analytical instruments and has established a "4+X" layout to become a leading domestic manufacturer in this field [1][3] - The company has made substantial improvements in gross margin and cost efficiency, with a comprehensive gross margin of 44.43%, an increase of 3.17 percentage points year-on-year [3][5] Financial Performance - In 2024, the company reported revenues from various segments: instruments (2.56 billion yuan, +15.36%), software and consumables (519 million yuan, +18.54%), testing services (426 million yuan, +7.14%) [3] - The company’s net profit is projected to grow significantly, with estimates of 352 million yuan in 2025, 507 million yuan in 2026, and 690 million yuan in 2027, reflecting growth rates of 70.2%, 44.0%, and 36.0% respectively [5][6] - The company has a stable cash dividend policy, distributing 2.50 yuan per 10 shares, totaling 112.18 million yuan [6] Business Strategy - The company is enhancing its high-end analytical instrument technology platforms, focusing on mass spectrometry, chromatography, and spectroscopy, with several products achieving international advanced or domestic leading levels [3][4] - The company is actively expanding into life sciences, establishing multiple business units to address clinical research and early disease diagnosis needs [4] - The company is optimizing its product performance and deepening collaborations with industry partners to explore practical applications of mass spectrometry technology in precision medicine [4]

Summary of Key Points from the Conference Call Industry Overview - The global mass spectrometry market is dominated by major players such as Thermo Fisher and Danaher, holding over 98% market share, with a market size of $7.7 billion in 2021 and a projected CAGR of over 7% from 2018 to 2026 [1][5] - In China, the mass spectrometry market was approximately 14 billion RMB in 2020, with a CAGR of nearly 20% from 2015 to 2020, and a decreasing reliance on imports [1][5] Core Insights and Arguments - The import value of mass spectrometers in China reached $1.5 billion in 2020, with over 30% sourced from the U.S. The main types dominating the market are LC-MS/MS and MALDI-TOF, each accounting for over 30% of the market share [1][6] - Significant progress has been made in domestic alternatives for MALDI-TOF, with 33 domestic devices approved by July 2024. The U.S. export restrictions on high-end LC-MS/MS starting January 2025 will impact China's biopharmaceutical research and development [1][8][7] - The Chinese government has implemented various policies to support domestic mass spectrometry alternatives, including promoting equipment upgrades and integrating mass spectrometers into county-level hospital standards [1][9] Market Dynamics - Domestic companies have made advancements in core components for MALDI-TOF and ICP-MS, but high-end general components still rely on imports [1][10][11] - The penetration rate of clinical mass spectrometry in China is significantly lower than in the U.S., indicating substantial growth potential. The market demand is expected to grow at a CAGR of nearly 20% from 2021 to 2030, driven by domestic needs [1][12] Company-Specific Developments - Focus on the performance of Ginkgo Technology, which reported over 3.6 billion RMB in revenue for 2024, a year-on-year increase of over 13%, and a net profit turnaround exceeding 160% due to strategic adjustments and robust growth in core business areas [1][13] - Ginkgo Technology's subsidiary, Puyou Technology, achieved over 1.4 billion RMB in revenue, contributing significantly to the parent company's performance. The company is actively involved in the clinical mass spectrometry and semiconductor detection sectors [1][14] Additional Important Insights - The ongoing U.S.-China geopolitical tensions are creating opportunities for domestic companies in the clinical mass spectrometry sector, as tariffs on U.S. imports exceed 100% [1][8] - The overall industry is expected to benefit from the dual dividends of domestic substitution and government support, with Ginkgo Technology positioned to capitalize on these trends [1][14]

Core Insights - The report indicates that as of April 21, 2025, a total of 170 institutional investors hold shares in 聚光科技, amounting to 239 million shares, which represents 53.20% of the company's total equity [1] - The top ten institutional investors collectively hold 41.25% of the shares, showing a decrease of 1.49 percentage points compared to the previous quarter [1] Institutional Holdings - The top ten institutional investors include notable entities such as 浙江睿洋科技有限公司, 中国建设银行股份有限公司, and 香港中央结算有限公司 [1] - The report highlights that there are five public funds that increased their holdings, accounting for a 2.53% increase, while twelve public funds reduced their holdings, representing a 0.52% decrease [2] - A total of 148 new public funds have disclosed their holdings this period, indicating active market participation [2] Foreign Investment - Only one foreign fund, 香港中央结算有限公司, increased its holdings, reflecting a 0.31% increase [2]

聚光科技（杭州）股份有限公司 审 计 报 告 众环审字（2025）0300224号 目 录 | | 起始页码 | | --- | --- | | 审计报告 | 1 | | 财务报表 | | | 合并资产负债表 | 1 | | 合并利润表 | 3 | | 合并现金流量表 | 4 | | 合并股东权益变动表 | 5 | | 资产负债表 | 7 | | 利润表 | 9 | | 现金流量表 | 10 | | 股东权益变动表 | 11 | | 财务报表附注 | 13 | 审计报告 众环审字（2025）0300224 号 聚光科技（杭州）股份有限公司全体股东： 一、 审计意见 我们审计了聚光科技（杭州）股份有限公司（以下简称：聚光科技公司）财务报表， 包括 2024 年 12 月 31 日的合并及公司资产负债表，2024 年度的合并及公司利润表、合并及 公司现金流量表、合并及公司股东权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制，公允反映 了聚光科技公司 2024 年 12 月 31 日合并及公司的财务状况以及 2024 年度合并及公司的经 营成果和现金流量。 二、 形 ...

关于聚光科技(杭州)股份有限公司 非经营性资金占用及 其他关联资金往来情况 汇总表的专项审核报告 众环专字(2025)0300046号 目 录 起始页码 专项审核报告 1-2 汇总表 非经营性资金占用及其他关联资金往来的情况汇总表 1 我们接受委托，在审计了聚光科技(杭州)股份有限公司（以下简称"聚光科技公司"） 2024 年 12 月 31 日合并及公司的资产负债表，2024 年度合并及公司的利润表、合并及公司 的现金流量表和合并及公司的股东权益变动表以及财务报表附注的基础上，对后附的《上市 公司 2024 年度非经营性资金占用及其他关联资金往来的情况汇总表》（以下简称"汇总表"） 进行了专项审核。按照中国证券监督管理委员会印发的《上市公司监管指引第 8 号——上市 公司资金往来、对外担保的监管要求》的规定，编制和披露汇总表、提供真实、合法、完整 的审核证据是聚光科技公司管理层的责任，我们的责任是在执行审核工作的基础上对汇总表 发表专项审核意见。 我们按照中国注册会计师审计准则的相关规定执行了审核工作。中国注册会计师审计准 则要求我们遵守中国注册会计师职业道德守则，计划和执行审核工作以对汇总表是否不存在 重 ...

聚光科技（杭州）股份有限公司 内部控制审计报告 众环审字（2025）0300225号 内部控制审计报告 众环审字（2025）0300225 号 聚光科技（杭州）股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审计了聚 光科技（杭州）股份有限公司（以下简称"聚光科技公司"）2024 年 12 月 31 日的财务报告 内部控制的有效性。 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计意见， 并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于情况的变化 可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内部控制审计结 果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 我们认为，聚光科技（杭州）股份有限公司于 2024 年 12 月 31 日按照《企业内部控制 基本规范》和相关规定在所有重大方面保持了有效的财务报告内部控制。 审计报告第 1页共 2 页 （此页无正文） 中审众环会计师事务所（特殊普通合伙） 中国注册会计师 ...

聚光科技（杭州）股份有限公司 独立董事 2024 年度述职报告 各位股东及股东代表： 本人作为聚光科技（杭州）股份有限公司（以下简称"公司"）的独立董事， 在 2024 年度严格按照《公司法》、《证券法》、《上市公司独立董事管理办法》、《深圳 证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》、《公司章 程》、《独立董事制度》等相关法律、法规的规定和要求，在 2024 年度工作中，诚实、 勤勉、独立的履行职责，积极出席相关会议，认真审议董事会各项会议议案，并对 相关事项发表独立意见，切实维护公司和股东特别是中小股东的利益。现将 2024 年度履行独立董事职责情况向各位股东汇报如下： 一、基本情况 本人陈伟华，1966 年 11 月出生,中国国籍,无境外居留权,硕士学位,法学教授, 兼职律师。现为杭州电子科技大学法学院法学教师,校信息化与法制发展研究所所长, 校妇联副主席(兼职)。2020 年 5 月至今任公司独立董事。兼任杭州雷迪克节能科技 股份有限公司独立董事。 在担任公司独立董事期间，本人未在公司担任除独立董事以外的任何职务，也 未在公司主要股东公司担任任何职务，不存在任何可能妨碍其进行 ...

聚光科技（杭州）股份有限公司 独立董事 2024 年度述职报告 各位股东及股东代表： 本人作为聚光科技（杭州）股份有限公司（以下简称"公司"）的独立董事， 在 2024 年度严格按照《公司法》、《证券法》、《上市公司独立董事管理办法》、《深圳 证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》、《公司章 程》、《独立董事制度》等相关法律、法规的规定和要求，在 2024 年度工作中，诚实、 勤勉、独立的履行职责，积极出席相关会议，认真审议董事会各项会议议案，充分 发挥独立董事的独立性和专业性作用，切实维护公司和股东特别是中小股东的利益。 现将 2024 年度履行独立董事职责情况向各位股东汇报如下： 在担任公司独立董事期间，本人未在公司担任除独立董事以外的任何职务，也 未在公司主要股东公司担任任何职务，不存在任何可能妨碍其进行独立客观判断的 关系，不存在影响独立董事独立性的情况。本人符合《上市公司独立董事管理办法》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等 法律法规及《公司章程》中关于独立董事的任职资格及独立性的相关要求。 一、基本情况 本人刘菁，1957 年 ...

聚光科技（杭州）股份有限公司 独立董事 2024 年度述职报告 各位股东及股东代表： 本人作为聚光科技（杭州）股份有限公司（以下简称"公司"）的独立董事， 在 2024 年度严格按照《公司法》、《证券法》、《上市公司独立董事管理办法》、《深圳 证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》、《公司章 程》、《独立董事制度》等相关法律、法规的规定和要求，在 2024 年度工作中，诚实、 勤勉、独立的履行职责，积极出席相关会议，认真审议董事会各项会议议案，并对 相关事项发表独立意见，切实维护公司和股东特别是中小股东的利益。现将 2024 年度履行独立董事职责情况向各位股东汇报如下： 在担任公司独立董事期间，本人未在公司担任除独立董事以外的任何职务，也 未在公司主要股东公司担任任何职务，不存在任何可能妨碍其进行独立客观判断的 关系，不存在影响独立董事独立性的情况。本人符合《上市公司独立董事管理办法》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等 一、基本情况 本人刘维屏，1958 年生，中国国籍，无境外永久居留权，博士研究生学历，1982 年浙江大学化学系毕业留 ...